We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement
Analytical Cannabis Logo
×

Home > News > Science & Health

CBD to be Trialed as Motor Neuron Disease Treatment in Humans

Published: Jul 18, 2018   

Complete the form below and we will email you a PDF version of "CBD to be Trialed as Motor Neuron Disease Treatment in Humans"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Analytical Cannabis?

Analytical Cannabis Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

CBD to be Trialed as Motor Neuron Disease Treatment in Humans

CannTrust has announced that it has partnered with Australia’s Gold Coast University Hospital (Gold Coast) to conduct a randomized, double-blind, placebo-controlled clinical trial to determine the efficacy of CannTrust cannabidiol (CBD) oil capsules in slowing the disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND). Patient safety and tolerability will also be assessed. The study has received Research Ethics Board approval and Australian Therapeutic Good Administration Acknowledgement for the study drug.


The six-month study will be led by Gold Coast Neurologist, Dr. Arman Sabet, MD. Gold Coast is one of Australia’s leading tertiary referral institutions for ALS management and Dr. Sabet has been involved in many international clinical trials specializing in neuromuscular disorders and stroke.


Dr. Sabet’s research will also analyze the effects of CannTrust CBD oil capsules on study participants’ spasticity, pain, weight loss and quality of life.


“ALS is a fatal disease with no known cure. This study will help advance our understanding of the potential effects of CannTrust’s standardized CBD oil capsules on ALS/MND, both as a disease modifying agent and as a symptomatic treatment and will become the basis for conducting future cannabinoid and ALS clinical trials,” said Dr. Sabet, MD, Senior Staff Specialist, Gold Coast University Hospital.


“The rate of ALS progression is often rapid, creating high levels of disability for patients. People diagnosed with ALS have an average life expectancy of 2.5 years. CannTrust is proud to participate in this important study which aims to help us better understand the potential impact of CannTrust CBD oil capsules on ALS and MND, so that patients might face better outcomes,” said Eric Paul, CEO, CannTrust.


This article has been republished from materials provided by CannTrust. Note: material may have been edited for length and content. For further information, please contact the cited source.

 

Like what you just read? You can find similar content on the topic tag shown below.

Science & Health

Stay connected with the latest news in cannabis extraction, science and testing

Get the latest news with the FREE weekly Analytical Cannabis newsletter

 
Advertisement